• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

辅助性佩南滨在 4-19 岁癫痫患儿中的长期疗效和安全性:一项真实世界研究。

Long-term efficacy and safety of adjunctive perampanel in pediatric patients aged 4-19 years with epilepsy: a real-world study.

机构信息

Department of Pediatrics, Yonsei University College of Medicine, Division of Pediatric Neurology, Severance Children's Hospital, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Department of Pediatrics, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150 Seongan-ro, Gangdong-gu, Seoul, 05355, Republic of Korea.

出版信息

Sci Rep. 2023 Sep 1;13(1):14369. doi: 10.1038/s41598-023-40594-8.

DOI:10.1038/s41598-023-40594-8
PMID:37658098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10474112/
Abstract

This study determined the 24-month outcomes of perampanel treatment in children and adolescents with epilepsy. The percentage of ≥ 50% responders was 47.3% (139/294) at 12 months and 49.0% (144/294) at 24 months. A 100% reduction in seizures for more than 12 months was observed in 12.2% (36/294). Discontinuation occurred in 39.8% (117/294). The most common reason for discontinuation was adverse events (29.1%, 34/117). Baseline seizure frequency was higher in children aged < 12 years than in patients aged ≥ 12 years; however, the percentage of seizure reduction and ≥ 50% responders did not significantly differ between the two groups. The rate of early discontinuation was higher (p < 0.001) and the duration of perampanel treatment was shorter in children aged < 12 years (p = 0.001). Most children aged < 12 years discontinued PER due to inadequate effectiveness, while adverse event was the most common reason in patients aged ≥ 12 years (p = 0.045). Only slow titration was significantly associated with ≥ 50% of responders. In conclusion, this study showed that perampanel can be utilized effectively and safely for a prolonged period in pediatric patients aged 4 to < 12 years, as well as in patients aged 12 years and older.

摘要

本研究旨在评估吡仑帕奈治疗儿童和青少年癫痫患者的 24 个月的疗效。12 个月和 24 个月时,应答率≥50%的患者比例分别为 47.3%(139/294)和 49.0%(144/294)。12 个月时,100%的患者癫痫发作减少持续超过 12 个月。39.8%(117/294)的患者停药。最常见的停药原因是不良事件(29.1%,34/117)。基线发作频率在<12 岁的儿童中高于≥12 岁的患者,但两组的发作减少率和应答率≥50%无显著差异。早期停药率较高(p<0.001),<12 岁儿童的吡仑帕奈治疗持续时间较短(p=0.001)。大多数<12 岁的儿童因疗效不足而停止使用 PER,而≥12 岁的患者因不良事件停药最常见(p=0.045)。仅缓慢滴定与应答率≥50%显著相关。总之,本研究表明,吡仑帕奈可有效、安全地用于 4 至<12 岁的儿童患者,以及 12 岁及以上的患者,持续时间较长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f92/10474112/d0542e0a91c5/41598_2023_40594_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f92/10474112/c9c7220ce8cc/41598_2023_40594_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f92/10474112/8764e5405e5d/41598_2023_40594_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f92/10474112/d0542e0a91c5/41598_2023_40594_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f92/10474112/c9c7220ce8cc/41598_2023_40594_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f92/10474112/8764e5405e5d/41598_2023_40594_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f92/10474112/d0542e0a91c5/41598_2023_40594_Fig3_HTML.jpg

相似文献

1
Long-term efficacy and safety of adjunctive perampanel in pediatric patients aged 4-19 years with epilepsy: a real-world study.辅助性佩南滨在 4-19 岁癫痫患儿中的长期疗效和安全性:一项真实世界研究。
Sci Rep. 2023 Sep 1;13(1):14369. doi: 10.1038/s41598-023-40594-8.
2
Real-world evaluation of perampanel effectiveness in Japanese adolescents with epilepsy.真实世界中评估吡仑帕奈在日本青少年癫痫患者中的疗效。
Epileptic Disord. 2022 Oct 1;24(5):813-821. doi: 10.1684/epd.2022.1454.
3
Efficacy, Tolerability, and Safety of Treatment With Perampanel in Pediatric Patients With Epilepsy Aged ≥4 Years: A Real-Life Observational Study.在年龄≥4 岁的癫痫儿科患者中使用吡仑帕奈的疗效、耐受性和安全性:一项真实世界观察性研究。
J Child Neurol. 2023 May;38(6-7):414-421. doi: 10.1177/08830738231182536. Epub 2023 Jun 22.
4
Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.辅助用吡仑帕奈对部分性发作青少年认知功能的长期影响。
Epilepsy Behav. 2018 Jun;83:50-58. doi: 10.1016/j.yebeh.2018.03.029. Epub 2018 Apr 10.
5
Adjunctive Perampanel in Older Patients With Epilepsy: A Multicenter Study of Clinical Practice.辅助性佩兰尼酮治疗老年癫痫患者:一项多中心临床实践研究。
Drugs Aging. 2021 Jul;38(7):603-610. doi: 10.1007/s40266-021-00865-3. Epub 2021 Jun 2.
6
Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.吡仑帕奈在药物难治性癫痫儿童及青少年中的疗效与耐受性:亚洲儿科神经科诊所的首次真实世界评估。
Epilepsy Behav. 2018 Aug;85:188-194. doi: 10.1016/j.yebeh.2018.06.033. Epub 2018 Jul 4.
7
Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.在真实环境中吡仑帕奈治疗12个月以上的安全性、有效性及与转归相关的因素:FYDATA研究
Epilepsy Res. 2016 Oct;126:201-10. doi: 10.1016/j.eplepsyres.2016.08.001. Epub 2016 Aug 4.
8
Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.一项开放性标签研究旨在调查附加性佩兰尼酮在未充分控制局灶性发作或全面强直阵挛性发作的儿科患者(4 岁至<12 岁)中的安全性和疗效。
Epilepsia. 2020 Jan;61(1):125-137. doi: 10.1111/epi.16413. Epub 2020 Jan 7.
9
Perampanel as adjunctive therapy in drug resistant epilepsy in adolescents and children waiting for epilepsy surgery: A multicenter observational study in Thailand.在等待癫痫手术的青少年和儿童中,作为辅助治疗药物的吡仑帕奈在耐药性癫痫中的应用:泰国的一项多中心观察性研究。
Seizure. 2022 Aug;100:103-108. doi: 10.1016/j.seizure.2022.06.015. Epub 2022 Jun 27.
10
Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open-label Study 342 (FREEDOM).在新诊断或当前未治疗的复发性癫痫患者中,使用培米贝罗尼单药治疗超越初始滴定以实现无发作的经验:开放性研究 342(FREEDOM)的事后分析。
Epilepsia Open. 2022 Mar;7(1):59-66. doi: 10.1002/epi4.12551. Epub 2021 Nov 19.

引用本文的文献

1
Efficacy and safety of adjunctive perampanel treatment in pediatric patients with epilepsy aged 4-12 years: a real-world study.在 4-12 岁癫痫患儿中添加普瑞巴林辅助治疗的疗效和安全性:一项真实世界研究。
J Neurol. 2024 Jul;271(7):4566-4576. doi: 10.1007/s00415-024-12416-y. Epub 2024 May 8.

本文引用的文献

1
Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.评估添加用吡仑帕奈治疗青少年癫痫患者的长期疗效和安全性:开放标签扩展研究的事后分析。
Epilepsy Behav. 2022 Oct;135:108901. doi: 10.1016/j.yebeh.2022.108901. Epub 2022 Sep 16.
2
Efficacy and adverse reactions of perampanel in the treatment of epilepsy in children.吡仑帕奈治疗儿童癫痫的疗效与不良反应
Front Neurol. 2022 Jul 27;13:924057. doi: 10.3389/fneur.2022.924057. eCollection 2022.
3
Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up.
长期随访中癫痫患者使用吡仑帕奈的疗效和耐受性。
Epilepsy Behav. 2021 Aug;121(Pt A):108069. doi: 10.1016/j.yebeh.2021.108069. Epub 2021 May 30.
4
Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.添加普瑞巴林辅助治疗青少年癫痫患者的有效性和安全性:六项随机研究的事后分析。
Epilepsy Behav. 2020 Mar;104(Pt A):106876. doi: 10.1016/j.yebeh.2019.106876. Epub 2020 Jan 16.
5
Real-Life Effectiveness and Tolerability of Perampanel in Pediatric Patients Aged 4 Years or Older with Epilepsy: A Korean National Multicenter Study.吡仑帕奈在4岁及以上癫痫患儿中的真实生活有效性和耐受性:一项韩国全国多中心研究。
J Clin Neurol. 2020 Jan;16(1):53-59. doi: 10.3988/jcn.2020.16.1.53.
6
Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.一项开放性标签研究旨在调查附加性佩兰尼酮在未充分控制局灶性发作或全面强直阵挛性发作的儿科患者(4 岁至<12 岁)中的安全性和疗效。
Epilepsia. 2020 Jan;61(1):125-137. doi: 10.1111/epi.16413. Epub 2020 Jan 7.
7
Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to <12 Years of Age With Epilepsy: Pharmacokinetics, Safety, Tolerability, and Efficacy.≥2至<12岁癫痫患儿辅助使用吡仑帕奈口服混悬液:药代动力学、安全性、耐受性和疗效
J Child Neurol. 2019 Apr;34(5):284-294. doi: 10.1177/0883073819827407. Epub 2019 Feb 10.
8
The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery.吡仑帕奈及靶向α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)传递对抗癫痫药物研发的影响
Expert Opin Drug Discov. 2019 Mar;14(3):195-197. doi: 10.1080/17460441.2019.1566318. Epub 2019 Jan 11.
9
Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy.吡仑帕奈辅助治疗难治性癫痫期间的不良事件。
J Clin Neurol. 2018 Jul;14(3):296-302. doi: 10.3988/jcn.2018.14.3.296.
10
Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.在 III 期随机试验的开放标签扩展研究中,接受添加性吡仑帕奈治疗长达 4 年的局灶性癫痫患者的最终安全性、耐受性和癫痫发作结局:研究 307。
Epilepsia. 2018 Apr;59(4):866-876. doi: 10.1111/epi.14044. Epub 2018 Mar 25.